Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immuron Limited ( (AU:IMC) ) has provided an update.
The Bank of New York Mellon Corporation (BNYMC) has increased its voting power in Immuron Limited from 34.17% to 42.69%, marking a significant change in its interest in the company. This increase in voting power could potentially impact Immuron’s strategic decisions and influence its market positioning, reflecting BNYMC’s growing influence and interest in the company’s operations.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapy products for the treatment of immune-mediated diseases and gut health. The company targets both human and animal health markets with its proprietary technology.
Average Trading Volume: 152,795
Technical Sentiment Signal: Sell
Current Market Cap: A$17.88M
For an in-depth examination of IMC stock, go to TipRanks’ Overview page.